Dexcom (DXCM) stock: key figures, P/E, revenue and dividend
Health Care · Health Care Equipment · United States · ISIN US2521311074
Dexcom financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 4.66 bn USD |
| Gross profit | 2.80 bn USD |
| Operating income | 911.80 m USD |
| EBIT | 994.00 m USD |
| Net income | 836.30 m USD |
| Diluted EPS – continuing operations | 2.09 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
More stocks
- Williams-Sonoma, Inc. (WSM)
- Svenska Handelsbanken AB (SHB A.ST)
- Heidelberg Materials (HEI.DE)
- Genmab AS (GMAB)
- Kraft Heinz (KHC)
- Zoom Communications, Inc. (ZM)
- Ameren (AEE)
- Dollar General (DG)
- Samsung SDI (006400.KS)
- Fox Corporation (Class A) (FOXA)
- Teck Resources Ltd (TECK)
- Reddit (RDDT)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.